The abstract is read at the publisher; the summary is JClub's.
Targeted anti-inflammatory and remodelling therapies for severe asthma and COPD are in development, focusing on Type 2 inflammation and intracellular signaling pathways like JAK and BTK.
- Why it matters: Current treatments have limited impact on inflammation and lung remodelling in COPD and leave some asthma patients with sub-optimal responses, highlighting gaps in subtype biology and treatment targeting.
- What they did: This narrative review summarizes emerging approaches under testing, including receptor agonists/antagonists and inhibitors of JAK and BTK, with an emphasis on using biomarkers to identify likely responders.
- The result: Trial successes and failures are used to infer disease mechanisms and potential responder/non-responder groups, suggesting that improved biomarker use could enable more precise, non-invasive treatment selection.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.